NCT07832123
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07832123
Title Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study (SAFU-G3)
Acronym SAFU-G3
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Zurich
Indications
Therapies
Age Groups: adult | senior
Covered Countries CHE


No variant requirements are available.